The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mamalyga M.L.

Kafedra anatomii i fiziologii cheloveka i zhivotnykh Moskovskogo pedagogicheskogo gosudarstvennogo universiteta, Moskva

Mamalyga L.M.

Institute of Biology and Chemistry of the Moscow Pedagogical State University, Moscow

Circadian changes in the structure of cardiac rhythm during pre-symptomatic and symptomatic stages of Parkinson’s disease

Authors:

Mamalyga M.L., Mamalyga L.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8): 85‑90

DOI: 10.17116/jnevro201811808185

Read: 1082 times

Download PDF (RU)
Contact the author
Table of contents

CIRCADIAN CHANGES IN THE STRUCTURE OF CARDIAC RHYTHM DURING PRE-SYMPTOMATIC AND SYMPTOMATIC STAGES OF PARKINSON’S DISEASE
CIRCADIAN CHANGES IN THE STRUCTURE OF CARDIAC RHYTHM DURING PRE-SYMPTOMATIC AND SYMPTOMATIC STAGES OF PARKINSON’S DISEASE

To cite this article:

Mamalyga ML, Mamalyga LM. Circadian changes in the structure of cardiac rhythm during pre-symptomatic and symptomatic stages of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8):85‑90. (In Russ.)
https://doi.org/10.17116/jnevro201811808185

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Vali­dation of ballistocardiography data for predicting the sleep effi­ciency in healthy indi­viduals and patients with inso­mnia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):60-66
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Chro­nic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
Influence of the method of manual-physical correction on auto­nomic regu­lation in patients with esse­ntial arte­rial hype­rtension. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):23-28
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Abstract:

Objective. To study circadian regulation of heart rhythm during the pre-symptomatic (PS) and early symptomatic (ESS) stages of Parkinson’s disease (PD) and determine the functionally most unfavorable periods during which there is a risk of life-threatening arrhythmias. Material and methods. The studies were performed on C57BL/6 mice. ECG monitoring was performed in online mode using a wireless telemetry system (ADInstruments Australia). Results. Characteristics of circadian changes heart rate during PS and ESS of PD were detected. During PS changes in the autonomic regulation of the heart occur at night. The increase at this time of the parasympathetic tone indicates compensatory mechanisms that prevent changes in the total power spectrum. However, they can’t prevent the high risk of life-threatening arrhythmias. The early symptomatic stage leads to the changes in mechanisms of not only sympathetic, but also parasympathetic regulation of the heart, increase in sympathetic tone and disturbed structure of the heart rhythm over most of the day. The decrease in the total power of the spectrum indicates a decrease in the adaptive capacity of the cardiovascular system. The increase in the intervals of QT, QTc and Tpeak Tend, indicates a risk of life-threatening arrhythmias. Conclusion. PD predetermines complications of circadian autonomic regulation of the heart during PS and ESS, which can become the pathogenetic basis for severe cerebrocardial disorders.

Keywords:

Parkinson’s disease
heart rate variability
life-threatening arrhythmia
autonomic balance

Authors:

Mamalyga M.L.

Kafedra anatomii i fiziologii cheloveka i zhivotnykh Moskovskogo pedagogicheskogo gosudarstvennogo universiteta, Moskva

Mamalyga L.M.

Institute of Biology and Chemistry of the Moscow Pedagogical State University, Moscow

Close metadata

References:

  1. Haapaniemi TH, Pursiainen V, Korpelainen JT, Huikuri HV, Sotaniemi KA, Myllylä VV. Ambulatory ECG and analysis of heart rate variability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70(3):305-310. https://doi.org/10.1136/jnnp.70.3.305
  2. Pursiainen V. Autonomic dysfunction in early and advanced Parkinson’s disease. University of Oulu, Finland. 2007. http://jultika.oulu.fi/files/isbn9789514283888.pdf
  3. Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson’s disease: An in vivo 11C-raclopride PET study. Experimental Neurology. 2008;214(1):112-116. https://doi.org/10.1016/j.expneurol.2008.07.021
  4. Seifried C, Boehncke S, Heinzmann J, Baudrexel S, Weise L, Gasser T, Eggert K, Fogel W, Baas H, Badenhoop K, Steinmetz H, Hilker R. Diurnal Variation of Hypothalamic Function and Chronic Subthalamic Nucleus Stimulation in Parkinson’s Disease. Neuroendocrinology. 2013;97(3):283-290. https://doi.org/10.1159/000343808
  5. Rieu I, Boirie Y, Morio B, Derost P, Ulla M, Marques A, Debilly B, Bannier S, Durif F. The Idiopathic Parkinson’s disease: A metabolic disease? Rev Neurol (Paris). 2010;166(10):822-828. https://doi.org/10.1016/j.neurol.2010.08.001
  6. Deguchi K, Sasaki I, Tsukaguchi M, Kamoda M, Touge T, Takeuchi H, Kuriyama S. Abnormalities of rate-corrected QT intervals in Parkinson’s disease — a comparison with multiple system atrophy and progressive supranuclear palsy. Journal of the Neurological Sciences. 2002;199(1-2):31-37. https://doi.org/10.1016/S0022-510X(02)00079-5
  7. Mokhles MM, Trifirò G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, Mazzaglia G, Herings R, Luise Cd, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, Camp Gv, Zanettini R, Sturkenboom MC. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacological Research. 2012;65(3):358-364. https://doi.org/10.1016/j.phrs.2011.11.009
  8. Oeda T, Masaki M, Yamamoto K, Mizuta E, Kitagawa N, Isono T, Taniguchi S, Doi K, Yaku H, Yutani C, Kawamura T, Kuno S, Sawada H. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson’s disease. J Neural Transm. 2009;116(2):171-178. https://doi.org/10.1007/s00702-008-0160-2
  9. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67(5):600-606. https://doi.org/10.1002/ana.21937
  10. Mamalyga ML. Cardiovascular dysfunctions in brain disorders and their treatment. Saarbrücken, Germany: Academic Publishing. 2017.
  11. Videnovic A, Willis GL. Circadian System — A Novel Diagnostic and Therapeutic Target in Parkinson’s Disease? Movement Disorders. 2016;31(3):260-269. https://doi.org/10.1002/mds.26509
  12. Khaindrava VG, Kozina EA, Kucherianu VG, Kryzhanovskiĭ GN, Kudrin VS, Klodt PD, Bocharov EV, Raevskiĭ KS, Ugriumov MV. Modeling of preclinical and early clinical stages of Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(7):41-47. (In Russ.)
  13. Khakimova GR, Kozina EA, Sapronova AYa, Ugryumov MV. Dopamine release in the substantia nigra and striatum at presymptomatic and early symptomatic stages in parkinsonian mice. Neurochemical Journal. 2011;5(1):35-41. (In Russ.) https://doi.org/10.1134/S1819712411010041
  14. Ugrumov MV, Khaindrava VG, Kozina E.A, Kucheryanu VG, Bocharov EV, Kryzhanovsky GN, Kudrin VS, Narkevich VB, Klodt PM, Rayevsky KS, Pronina TS. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience. 2011;181(5):175-188. https://doi.org/10.1016/j.neuroscience.2011.03.007
  15. Jost WH. Autonomic dysfunction in idiopathic Parkinson’s disease. J Neurol. 2003;250(1):128-130. https://doi.org/10.1007/s00415-003-1105-z
  16. Korchounov A, Kessler KR, Yakhno NN, Damulin IV, Schipper HI. Determinants of autonomic dysfunction in idiopathic Parkinson’s disease. J Neurol. 2005;252(12):1530-1536. https://doi.org/10.1007/s00415-005-0909-6
  17. Magenkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res. 2005;15(2):76-82. https://doi.org/10.1007/s10286-005-0253-z
  18. Ugryumov MV. Expression of the enzymes of dopamine synthesis in mediumenergy neurons: functional significance and regulation. Uspekhi fiziologicheskih nauk. 2007;38(4):3-20. (In Russ.) http://www.fesmu.ru/elib/Article.aspx?id=171972
  19. Saper CB, Scammell TE, Lu J. Review Article Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257-1263. https://doi.org/10.1038/nature04284
  20. Chou ThC, Scammell Th E, Gooley JJ, Gaus SE, Saper CB, Lu J. Critical Role of Dorsomedial Hypothalamic Nucleus in a Wide Range of Behavioral Circadian Rhythms. Journal of Neuroscience. 2003;23(33):10691-10702. https://www.ncbi.nlm.nih.gov/pubmed/14627654
  21. Manni R, Terzagh, M, Pacchetti C, Nappi G. Sleep disorders in Parkinson’s disease: facts and new perspectives. Neurol Sci. 2007;28(1):1-5. https://doi.org/10.1007/s10072-007-0731-2
  22. Bhidayasiri R, Truong DD. Therapeutic strategies for nonmotor symptoms in early Parkinson’s disease: the case for a higher priority and stronger evidence. Parkinsonism Relat Disord. 2012;18(1):110-113. https://doi.org/10.1016/S1353-8020(11)70035-9
  23. Baevsky PM, Ivanov GG. Heart rate variability: theoretical aspects and possibilities of clinical application. Ul’trazvukovaya i funkcional’naya diagnostika. 2001;3:106-127. (In Russ.) https://elibrary.ru/item.asp?id=25990135
  24. Vein AM. Autonomic disorders: clinical picture, diagnosis, treatment. M.: MIA; 2003. (In Russ.) http://www.booksmed.com/nevrologiya/77-vegetativnye-rasstrojstva-vejn-klinika.html
  25. Oka H, Mochio S, Onouchi K, Morita M, Yoshioka M, Inoue K. Cardiovascular dysautonomia in de novo Parkinson’s disease. Neurol Sci. 2006;241(1-2):59-65. https://doi.org/10.1016/j.jns.2005.10.014
  26. Pursiainen V, Haapaniemi TH, Korpelainen JT, Huikuri HV, Sotaniemi KA, Myllylä VV. Circadian heart rate variability in Parkinson’s disease. J Neurology. 2002;249(11):1535-1540. https://doi.org/10.1007/s00415-002-0884-0
  27. Mamalyga ML, Mamalyga LM. Influence of pre-symptomatic and symptomatic stages of Parkinson’s disease and its treatment upon changes of variability of cardiac rhythm. Romanian Journal of Neurology. 2017;16(1):9-14. https://view.publitas.com/amph/rjn_2017_1_art-02/page/1
  28. Devos D, Kroumova M, Bordet R, Vodougnon H, Guieu JD, Libersa C, Destee A. Heart rate variability and Parkinson’s disease severity. J Neural Transm (Vienna). 2003;110(9):997-1011. https://doi.org/10.1007/s00702-003-0016-8
  29. Haapaniemi T. Autonomic dysfunction in Parkinson’s disease and its correlates to medication and dopamine transporter binding. Oulu University Press. Finland. 2001. http://jultika.oulu.fi/Record/isbn951-42-5963-7
  30. Fuller RW, Hemrick-Luecke SK, Perry KW. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Pharmacol Exp Ther. 1988;247(2):531-535. https://www.ncbi.nlm.nih.gov/pubmed/3141609
  31. Algeri S, Ambrosio S, Garofalo P, Gerli P. Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat. European Journal of Pharmacology. 1987;141(2):309-312. https://www.ncbi.nlm.nih.gov/pubmed/3500067
  32. Ren J, Porter JE, Wold LE, Aberle NS, Muralikrishnan Dh, Haselton JR. Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse. Neurobiology of Aging. 2004;25(1):131-138. https://doi.org/10.1016/S0197-4580(03)00035-6
  33. Ambrosio S, Blesa R, Mintenig GM. , Palacios-Araus L, Mahy N, Gual A. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat. Toxicology Letters. 1988;44(1-2):1-6. https://www.ncbi.nlm.nih.gov/pubmed/3263717
  34. Korshunov KS, Blakemore LJ, Trombley PQ. Dopamine: A Modulator of Circadian Rhythms in the Central Nervous System. Front Cell Neurosci. 2017;11(2):91-110. https://doi.org/10.3389/fncel.2017.00091
  35. Verwey M, Dhir S, Amir Sh. Circadian influences on dopamine circuits of the brain: regulation of striatal rhythms of clock gene expression and implications for psychopathology and disease. F1000Res. 2016;5:F1000 Faculty Rev-2062. https://doi.org/10.12688/f1000research.9180.1
  36. Yujnovsky I, Hirayama J, Doi M. Borrelli E, Sassone-Corsi P. Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK: BMAL1. Proc Natl Acad Sci USA. 2006;103(16):6386-6391. https://doi.org/10.1073/pnas.0510691103
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.